← All stocks

CORCEPT THERAPEUTICS INC

CORT Net selling

CIK 0001088856 #827 in the set updated 21 Sep 2026

Bought (12 mo)

$3.31M

out of their own pocket, the only kind of buying there is

Sold (12 mo)

$102.52M

$30.01M on a plan · $68.79M straight out of an exercise

Sold at will

$3.72M

5 of 109 sales

Net

−$99.20M

−$404.15K against sales at will

By person

14 insiders · 122 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Maduck Sean

See Remarks

—

$23.27M (20) scheduled

−$23.27M

53,938

0.0499%

$5.44M

+37.0%

Mokari Atabak

Chief Financial Officer

—

$18.73M (22) scheduled

−$18.73M

16,304

0.0151%

$1.64M

+30.2%

Guyer William

Chief Development Officer

—

$14.91M (19) scheduled

−$14.91M

4,313

0.0040%

$434.84K

−25.6%

MAHONEY DAVID L

Director

—

$13.94M (5) scheduled

−$13.94M

1,133,539

1.05%

$114.28M

−8.0%

BELANOFF JOSEPH K

Chief Executive Officer

—

$13.79M (11) scheduled

−$13.79M

2,565,489

2.37%

$258.65M

−5.8%

Vieira Roberto Wandenkolk

President, Oncology

—

$6.49M (8) scheduled

−$6.49M

3,946

0.0037%

$397.84K

−3.0%

WILSON JAMES N

Director

—

$3.94M (12) scheduled

−$3.94M

2,539,086

2.35%

$255.99M

−22.8%

BAKER G LEONARD JR

Director

$3.31M (2)

—

+$3.31M

2,241,893

2.07%

$226.03M

+12.0%

Park Kimberly

Director

—

$3.27M (1) scheduled

−$3.27M

0.0000%

$0.00

—

Lyon Joseph Douglas

See Remarks

—

$2.83M (9) scheduled

−$2.83M

5,683

0.0053%

$572.96K

−42.6%

Robb Gary Charles

Chief Business Officer

—

$1.16M (1)

−$1.16M

126,159

0.1167%

$12.72M

+92.9%

Swisher Daniel N JR

Director

—

$192.59K (1) scheduled

−$192.59K

0.0000%

$0.00

—

Hunt Hazel

Chief Scientific Officer

—

255,437

0.2363%

$25.75M

+115.4%

Cannon Gillian

Director

—

0.0000%

$0.00

—

Individual transactions

Insider

Date

Role

Action

Price

Amount

BAKER G LEONARD JR

17 Mar 2026

Director

Buy

24,218

$33.56

$812.84K

BAKER G LEONARD JR

17 Mar 2026

Director

Buy

75,782

$33.00

$2.50M

Show all 122 transactions →

What was left out

Form 4 filings counted 100

Amendments (4/A) skipped 1

Filings about a different issuer 0

Unreadable filings 0

Joint filings 0

Sales on a Rule 10b5-1 plan 28

Sales straight out of an exercise 76

Sales at will 5

Transactions with no price 0

Shares from compensation/vesting 5,635,985

History held since 9 Nov 2016